Preparation and evaluation of 131I-quercetin as a novel radiotherapy agent against dedifferentiated thyroid cancer
- 226 Downloads
Here we reported the radiolabeling and evaluation of a novel 131I-radiolabeled quercetin for the treatment of dedifferentiated thyroid cancers. The human thyroid cancer cell lines (FTC-133, TT and DRO) experienced much higher uptake of 131I-quercetin as compared to the free 131I. And the proliferation inhibition rate of 131I-quercetin on in vitro DRO cell line was 86.87 ± 7.15%. Biodistribution and SPECT analysis demonstrated that the injected radioactivity mainly accumulated in tumors. The tumor volume in the treatment group was dramatically inhibited in comparison with the control group.
KeywordsDedifferentiated thyroid cancer 131I-quercetin Proliferation inhibition Biodistribution Radiopharmaceutical
This work was financially supported by the National Science and Technology Support Program (2014BAA03B00), the National Fund for Fostering Talents of Basic Science (J1210004), the National Natural Science Foundations of China (81271526), and University of Macau Research Fund (SRG2014-00025-ICMS-QRCM). We also wish to thank the Comprehensive Training Platform of specialized laboratory at College of Chemistry in Sichuan University (Chengdu, China), and the Analytical & Testing Center at Sichuan University (Chengdu, China) for providing analytical equipment. We are also much grateful to Nuclear Medicine Program of West China Medical School, Sichuan University, for providing various cancer cell lines and the SPECT scan.
Compliance with ethical standards
All procedures performed in studies involving mice were in accordance with the ethical standards of Sichuan University and Harbin Medical University. This study was approved by the animal ethics committee of Sichuan University, where the mice were bred and tested.
- 2.Nguyen QT, Lee EJ, Huang MG et al (2015) Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benef 8(1):30–40Google Scholar
- 3.Zarebczan B, Chen H (2010) Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir 65(1):59–69Google Scholar
- 9.Antonelli A, Ferri C, Ferrari SM et al (2009) New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol 2010(1):6Google Scholar
- 21.Duo J, Ying GG, Wang GW et al (2012) Quercetin inhibits human breast cancer cell proliferation and induces, apoptosis via bcl-2 and bax regulation. Molec Med Rep 5(6):1453–1456Google Scholar
- 25.Fang MZ, Wang Y, Ai N et al (2003) Tea polyphenol (−)-epigallocatechin-3-gallate inhibits dna methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63(22):7563–7570Google Scholar
- 27.Iwanami T (2011) New generation of enantioenriched allylsilanes. Radiother Oncol 104(3):395–400Google Scholar
- 28.Chen L (2012) Autophagy plays a role in promoting radiosensitivity of glioma stem/progenitor cells by quercetin. J Radiat Res Radiat Process 30(5):297–302Google Scholar
- 30.Phani CR, Vinaykumar C, Rao K et al (2010) Quantitative analysis of quercetin in natural sources by RP-HPLC. Int J Res Pharm Biomed Sci 1(1):19–22Google Scholar
- 31.Verma N, Trehan N (2013) HPLC analysis of methanolic extract of herbs for quercetin content. J Pharmacogn Phytochem 2(1):159–162Google Scholar
- 42.Walle T, Walle UK, Halushka PV (2001) Carbon dioxide is the major metabolite of quercetin in humans. J Nutr 131(10):2648–2652Google Scholar